Mode
Text Size
Log in / Sign up
N/A Completed N=42

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Source: ClinicalTrials.gov NCT00615290 ↗
Enrolled (actual)
42
Serious AEs
7.1%
Results posted
Feb 2010
Primary outcomePrimary: Number of Patients With a Viral Load< 50 Copies/mL and a Gain in CD4 Higher Than 100 Cells/mm3 — 8 participants

Summary

To obtain information on clinical practices for patients treated by Aptivus in real life

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With a Viral Load< 50 Copies/mL and a Gain in CD4 Higher Than 100 Cells/mm3
8 —
SECONDARY
Evaluation of Early Virological Response
20 —
SECONDARY
Viral Load Response at 1 Month
71.5 —
SECONDARY
CD4 Count at 1 Month
349.0 —
SECONDARY
Evaluation of Intermediate Virological Response, Viral Load < 400 Copies/mL
28 —
SECONDARY
Evaluation of Intermediate Virological Response, Viral Load < 50 Copies/mL
24 —
SECONDARY
Viral Load Response at 3 Months
49 —
SECONDARY
CD4 Count at 3 Months
322.5 —
SECONDARY
Patient Self Perception of the New Treatment
59; 76; 74 —

Eligibility Criteria

Inclusion Criteria

  • HIV positive patients for whom Aptivus treatment is initiated by their physician
  • Aptivus SCP respect

Exclusion Criteria

None if the inclusion criteria are respected: observational study

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00615290). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search